Alev Yilmaz's research while affiliated with Istanbul University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publication (1)
Bakcground
The aim of this study was to evaluate the efficacy and safety of citrate versus heparin anticoagulation for CRRT in critically-ill children.
Methods
This retrospective comparative cohort reviewed the clinical records of critically-ill children undergoing CRRT with either RCA or systemic heparin anticoagulation. The primary outcome measu...
Citations
... In the current issue of Pediatric Research, Atis et al. reported their experience treating 131 critically ill children on CKRT with systemic heparin or regional citrate anticoagulation (RCA) in a tertiary PICU located in Istanbul. 2 Here, we will review the advantages and disadvantages of the two anticoagulant strategies and discuss key points relevant to the study of Atis et al. Systemic unfractionated heparin (UFH) was the first-choice anticoagulant used in the 90 s for CKRT, given the experience available using heparin in hemodialysis, its low cost and efficacy to prevent thrombotic events, and rapid reversal with protamine. ...
